INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Buy” from Brokerages

Shares of INmune Bio, Inc. (NASDAQ:INMB) have received a consensus rating of “Buy” from the six analysts that are presently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $22.80.

A number of analysts recently issued reports on the stock. Scotiabank increased their price target on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Tuesday, February 11th. RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Maxim Group raised their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, Rodman & Renshaw assumed coverage on shares of INmune Bio in a research report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price target for the company.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Laird Norton Wetherby Trust Company LLC boosted its stake in shares of INmune Bio by 3.8% in the fourth quarter. Laird Norton Wetherby Trust Company LLC now owns 34,100 shares of the company’s stock valued at $159,000 after purchasing an additional 1,250 shares during the period. Financial Advocates Investment Management lifted its stake in INmune Bio by 14.8% in the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after acquiring an additional 2,000 shares during the last quarter. Wells Fargo & Company MN lifted its stake in INmune Bio by 51.0% in the fourth quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock worth $30,000 after acquiring an additional 2,155 shares during the last quarter. Rhumbline Advisers lifted its stake in INmune Bio by 16.9% in the fourth quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock worth $78,000 after acquiring an additional 2,424 shares during the last quarter. Finally, Barclays PLC lifted its stake in INmune Bio by 10.2% in the fourth quarter. Barclays PLC now owns 32,019 shares of the company’s stock worth $150,000 after acquiring an additional 2,975 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Price Performance

INMB stock opened at $9.51 on Thursday. The firm’s fifty day simple moving average is $6.85 and its 200-day simple moving average is $6.14. The company has a market capitalization of $210.77 million, a P/E ratio of -4.36 and a beta of 1.87. INmune Bio has a 12 month low of $4.32 and a 12 month high of $14.41.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.